Background Little is known about the origin of methylenedioxymethamphetamine (MDMA, ecstasy). The most commonly repeated statement in the medical literature is that MDMA was synthesized by the German pharmaceutical company Merck in 1912 in order to develop an appetite suppressor. Aim To reconstruct the true story of the first known description of MDMA at Merck using the original documents. Methods A systematic analysis of the original documents in Merck's historical archive in Darmstadt, Germany, was conducted (years 1900-60). Results There were no indications for plans to develop an appetite suppressant at Merck between 1900 and 1960. Although MDMA was, in fact, first synthesized at Merck in 1912, it was not tested pharmacologically because it was only an unimportant precursor in a new synthesis for haemostatic substances. The new pathway was patented in order to evade an existing patent by a local competitor. MDMA was called 'Methylsafrylamin' in 1912. In 1927 and 1959, the pharmacological effects of MDMA were studied at Merck, but not in humans. Discussion A systematic analysis of the original documents in the company's archive revealed that uncritical copy-paste procedures may have contributed to the famous myth that MDMA was patented as an appetite suppressor in 1912.
INTRODUCTION
The ring-substituted amphetamines methylenedioxymethamphetamine (MDMA) and its analogues, better known as 'ecstasy', have been among the most popular illegal psychotropic drugs since the mid-1980s [1] [2] [3] . Contrary to expectation, MDMA was discovered much earlier.
In the medical literature it is usually maintained that MDMA was first synthesized and patented by the German pharmaceutical company Merck in Darmstadt around 1912, with plans to market an 'anorectic drug' or 'appetite suppressor'. This statement has been repeated almost verbatim in reviews [1, [4] [5] [6] [7] [8] [9] , textbooks [10] , original articles [11] and also in American Federal sources such as websites of the US Drug Enforcement Administration [12] . Only a few authors have questioned the 'Merck story' [13] [14] [15] [16] . These works, however, as well as the small number of papers that deal specifically with the history of MDMA, do not provide detailed information about the substance's first known description [14, 15, [17] [18] [19] .
It was our aim to reconstruct the true story about the origin of MDMA by means of the first systematic analysis of the original documents in Merck's historical archive in Darmstadt, Germany. (An unsystematic search of the Merck archive was performed around 1996 by the student Christian Beck. Some of his findings were published in German a few years later [18] . We would like to credit him for the idea to examine the Merck archive for MDMArelated material.)
METHODS
For the analysis, an interdisciplinary work group comprising a pharmacist specialized in the history of pharmacy (S. B. R.), a chemist (F. Ö.) and a physician (R. W. F.) was set up. All available documents in Merck's archive from 1900 to 1960 (patents, laboratory journals, annual laboratory reports, letters, interviews, memoirs, etc.) were searched systematically for MDMA-related information by hand-search or digitally (e.g. using internal databases). The search took into account that MDMA had several other names at Merck (see Results). All retrieved documents were evaluated in the context of the history of pharmacy. For patent law-related issues we collaborated with an international patent lawyer (Sabine Schoen, Merck). The archive work was conducted between February 2004 and March 2005. It was part of our project to digitize important documents in order to make them more accessible for the scientific community.
RESULTS
We identified MDMA-related documents in Merck's archive dating back to the years 1912, 1927, 1952 and 1959 .
Our archive analysis confirmed that MDMA was, in fact, first synthesized at Merck as early as 1912, as proved by two documents which described explicitly the making of MDMA. The first is a German patent with the number 274350, from which both the original patent instrument ('Patent-Urkunde') and the patent specification ('Patentschrift') were retrieved (Fig. 1) . The second is the Annual Report for 1912 ( Jahresbericht für 1912 ) of Merck's 'Scientific Laboratory' (the German phrases are direct quotes from the documents, and English citations are direct translations from the German originals).
However, in these documents there were no indications for plans to develop an appetite suppressant . MDMA was mentioned only casually and without being called 'MDMA'. In the patent specification, MDMA appeared only as a chemical formula and in the annual report it was referred to as 'Methylsafrylamin'. The accurate background for the first synthesis of MDMA was that Merck wanted to find and patent pathways leading to haemostatic substances, not appetite suppressors. The company tried to evade an existing patent for the synthesis of a clotting agent called 'Hydrastinin' held by the German competitor Farbenfabriken Elberfeld und Decker or Bayer/ Elberfeld, as stated explicitly by the head of Merck's laboratory, Dr Walter Beckh (1870-1915) in the Annual Report for 1912 .
Beckh and his coworker, Dr Otto Wolfes (1895-1942), believed that the methylated analogue of hydrastinin, methylhydrastinin, might be similarly effective. They requested the third laboratory member, Dr Anton Köllisch (? − 1916), to develop syntheses for methylhydrastinin and new patentable syntheses for hydrastinin.
Once available, methylhydrastinin was tested at Merck's laboratory and externally (Dr Gustav Landmann, Frankfurt, and Professor Robert Heinz, Erlangen). It proved to be equivalent to the reference haemostatics hydrastinin and cotarnin. Methylhydrastinin was also tested in humans in 1912 in a Berlin hospital. Results must have been promising, because Köllisch later worked on a higher yield of the synthesis. The new syntheses were then secured by patent 274350 and a second patent filed on Christmas Eve 1912 (patent 279194, 'Verfahren zur Darstellung von Hydrastinin-Derivaten').
According to the patent instrument the patent 274350 was assigned 'to the company E. Merck in Darmstadt' by the German Imperial Patent Office in Berlin (Fig. 1) . It began on 24 December 1912, when the application for the patent was filed. The patent specification described the newly developed chemical reactions starting from different basic compounds with examples. In the fourth example, MDMA was mentioned without a name as one of many chemical intermediates (CH 2 · O 2 : C 6 H 3 · CH 2 · CH (CH 3 ) · NH · CH 3 ) with some chemical properties [e.g. colourless oil, boiling point 155 ° (Celsius) at 20 mm pressure, its salt forms white crystals which boil at 148-150 ° ]. There were no signs of a particular interest in MDMA. The reaction leading to MDMA results from the addition of aqueous hydrobromic acid (HBr) to safrole and goes via MDA. The patent stated explicitly that the products of the synthesis were 'important intermediates for the manufacturing of therapeutically effective compounds', but the main background for the new syntheses (clotting agents) was not mentioned. Instead, Merck protected the whole group of reactions leading to the 'alkyloxyaryl-, dialkyloxyaryl-and alkylendioxyarylaminopropanes' described in the patent specification.
For the next 15 years MDMA was not mentioned in the archive files. In 1927, Merck's laboratory was interested in adrenaline-or ephetonine-like substances on the basis of safrole. Merck's chemist, Dr Max Oberlin (1896-?), noted MDMA's structural similarity to ephetonine and adrenaline and probably rediscovered patent 274350 because it also began from safrole and expired in 1927. After some basic chemical studies he compared MDMA, now called 'Safryl-methyl-amin', and its two analogues 'Eugenyl-methyl-amin' and 'Methyl-eugenyl-methylamin' with ephetonine according to the Annual Report for 1927 . As far as is known, these investigations were the first proven pharmacological tests with MDMA. MDMA was transformed from a free base to a hydrochloride salt for the testing. Unfortunately, no further details about the experimental setting could be found. MDMA's effects on blood glucose levels were comparable to high doses of ephetonine. MDMA was as effective as ephetonine at vascular smooth muscle tissue and stronger at the uterus, but devoid of a 'local effect at the eye'. Oberlin concluded that the substance does not have 'pure sympathetic effects'. MDMA showed the highest toxicity of the three bases and ephetonine. Despite these 'partly remarkable results of the pharmacological testing' the research was halted, 'particularly due to a strong price increase of Safryl-Methyl-Amin (intermediate in the synthesis of methylhydrastinin) in the meantime'. Oberlin recommended 'to keep an eye on this field'. He also provided the oldest structural formula of MDMA known today.
The 
DISCUSSION
The true story about the origin of MDMA at the German pharmaceutical company Merck was reconstructed by the first systematic analysis of the original documents in the company's archive. Many important files, such as the oldest proven records of MDMA (patent 274350, Annual Report for 1912 ), were discovered, digitized and made accessible for the community.
The most important finding was that Merck did not want to produce and patent an appetite suppressor when MDMA was first synthesized in 1912, in clear contrast to what is usually claimed by the 'ecstasy' literature. MDMA was neither studied in animals nor humans at Merck around 1912. The first basic pharmacological tests using MDMA were performed by the company's chemists decades later (1927, 1952) , but there was no indication of MDMA testing in humans until 1960. In 1912, the substance was merely a precursor in a new chemical pathway which was patented in order to avoid an existing patent for the synthesis of the clotting agent hydrastinine. MDMA, like other intermediates, became patented inadvertently because they were covered by the patent claim in the patent specification 274350. From a legal perspective, patent 274350 was a procedure patent. Substance patents were unknown in the German Empire in 1912.
An explanation for the erronious association of MDMA with appetite suppressors might be that MDMA's analogue MDA was studied for its potential as an antidepressant and appetite suppressor by Smith, Kline and French between 1949 and 1957 [20, 21] .
Dr Anton Köllisch can be regarded as the person who first described a synthesis for MDMA. Accordingly, our archive search disproved that MDMA was discovered by German chemists Mannich and Jacobsohn around 1900 [10] or German Nobel Price winner for Chemistry Fritz Haber (1868-1934) [22] , as reported by some authors.
For a better overview on the history of MDMA/ecstasy we have summarized briefly the major milestones from the 'Merck era' and beyond in Table 1 .
CONCLUSIONS
Uncritical 'copy-paste' procedures in the ecstasy literature may have contributed to the formation of the myth that MDMA was developed as an appetite suppressor at the German pharmaceutical company Merck just before World War I. The true story about the origin of MDMA was reconstructed by checking primary sources in the company's archive.
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